Blood cancers

Second TKI listed on PBS for adults with Ph+ALL 

Patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) will have subsidised access to dasatinib (Sprycel) from August 1. Newly diagnosed adult patients (aged 18 years and over) Ph+ ALL will be eligible for PBS subsidised treatment with the TKI  as a first line oral therapy, when this is integrated with chemotherapy. Professor Andrew Grigg, Director of Clinical Haematology ...

Already a member?

Login to keep reading.

© 2021 the limbic